Steven David
@drspdavid
Followers
516
Following
487
Media
25
Statuses
253
Radiation Oncologist at the Peter MacCallum Cancer Centre. Views are my own, healthy skeptic. #radonc
Joined December 2015
🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. https://t.co/g63BysQ8xJ
3
28
55
Extraordinary case at #SABR2025 by @drspdavid and De Mark Shaw @PeterMacRadOnc oligoprogressive #breastcancer without switching drug therapy. 8 years of SABR with #radonc, with preserved quality of life from the patient’s perspective!!! #bcsm
3
12
52
Register now for the next FREE #RSSwebinar on "The Role of Metastasis-Directed Therapy for Oligometastases and Oligoprogression in Breast Cancer" on 10/9 at noon ET featuring @drspdavid, @r_glicksman and @WinstonVuong; moderated by @radicalonc. https://t.co/pPdjQRRtiX
0
8
9
Congrats to Dr. Belle Sasse on this impactful study! 🎉 Collaboration between @MonashHealth & @PeterMacRadOnc shows metastatic breast MDMs changed treatment plans in 28.1% of patients, highlighting their invaluable role in care. 👉 Read: https://t.co/qXwD1f58oy
3
5
15
🚩 Sharing our latest article: Here we show that dose dense AC-T, radiotherapy & age affects long-term lymphocyte counts post adjuvant #breastcancer treatment ?implications for IO therapy https://t.co/Lbh4W0Hgh9 👏 @J_DixonDouglas @GustaveRoussy @PeterMacRes @BCRFcure
nature.com
npj Breast Cancer - Sustained lymphocyte decreases after treatment for early breast cancer
1
15
46
Wonderful summary on #oligometastatic disease and #oligoprogression in #breastcancer by excellent speakers Prue Francis and @drspdavid
@BCTrialsANZ #bct2024 Looking forward to AVATAR-2 ⚡️⚡️ @PeterMacRadOnc
0
4
14
Our phenomenal #radonc team!! A superbly productive and energising day of aspirations and strategic planning @PeterMacRadOnc
#thefutureisbright 😎 @PeterMacCC @svporceddu
3
7
43
Big thank you to @TROGfightcancer and my supportive supervisor @drspdavid @PeterMacRadOnc for a fantastic opportunity to speak at this year’s ASM #TROG2024 #TROGASM24
The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!
1
3
21
The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!
0
3
15
@piet_ost argues the case for SABR in oligometastatic #prostatecancer - a low toxicity intervention. To better select for patients who benefit most, think biomarkers of the future (genomics), and a role for SABR in mCRPC from ARTO trial #pcsm #radonc #SABR2023
1
6
30
0
4
17
Metastatic #breastcancer at #COSA23 . A/Prof Steven David takes the stage to discuss future directions in #oligometastatic breast cancer care. Alongside A/Prof Shom Goel & Dr Stephen Luen (also from @PeterMacCC) & Kerry Patford, breast care nurse. 👏 @drspdavid @COSAoncology
0
2
11
A/Prof Steven David sharing a phase 2 trial of stereotactic #radiotherapy for oligoprogressive ER positive breast #cancer #RANZCR2023
0
2
16
@drspdavid @learningonco @heitorvbrito #AVATAR was a standout at ASTRO this year. Kudos for the remarkable effort!
0
1
4
The COSA AM is in Melbourne this November. It's a highlight of the Australian oncology calendar, and I'm looking forward to presenting on oligometastatic breast cancer. Registrations are at https://t.co/ZafaUHEt89 Hoping to see you there! #COSA23
0
3
25
7
38
78
Congratulations @drspdavid 👏👏😊 huge amount of work, presented so clearly and with beautiful slides ☺️ @PeterMacRadOnc @PeterMacRes @TROGfightcancer #breastcancer team #ASTRO2023
@drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!
0
3
13
@drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!
3
31
68